The present invention relates to the compounds of formula (I), and the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variables are defined according to the description. The compounds of formula (I), as well as the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof, are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to plant propagation material and to an agricultural and a veterinary composition comprising said compounds.
Compounds having the formula
are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
[EN] BICYCLIC COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS<br/>[FR] COMPOSÉS BICYCLIQUES DESTINÉS À ÊTRE UTILISÉS EN TANT QU'INHIBITEURS DE LA KINASE RIP1
申请人:HOFFMANN LA ROCHE
公开号:WO2019072942A1
公开(公告)日:2019-04-18
The invention provides novel compounds having the general formula (I) or pharmaceutically acceptable salts thereof, wherein RA, RB1, RB2, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds as RIP1 kinase inhibitors.
[EN] ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF<br/>[FR] ISOXAZOLIDINES EN TANT QU'INHIBITEURS DE RIPK1 ET LEUR UTILISATION
申请人:SANOFI SA
公开号:WO2021245070A1
公开(公告)日:2021-12-09
The present invention relates to isoxazolidines of formula I and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase (1) such as rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease (IBD), Crohn's disease or ulcerative colitis.
recently discovered a novel reaction between iminosydnones and strained alkynes leading to two products resulting from ligation and fragmentation of iminosydnones under physiological conditions. We now report the synthesis of a panel of substituted iminosydnones and the structure reactivity relationship between these compounds and strained alkyne partners. This study identified the most relevant substituents